Genetic regulation of serum cytokines in systemic lupus erythematosus

Translational Research

Volumn 155, Issue 3, 2010, Pages 109-117

  Kariuki, Silvia N ^a   Niewold, Timothy B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; DNA POLYMORPHISM; GENE CONTROL; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 76549136591     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.08.012     Document Type: Review

References (70)

1. Chun H.Y., Chung J.W., Kim H.A., et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27 (2007) 461-466
2. Liu T.F., and Jones B.M. Impaired production of IL-12 in system lupus erythematosus. II: IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE. Cytokine 10 (1998) 148-153
3. Grondal G., Gunnarsson I., Ronnelid J., Rogberg S., Klareskog L., and Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 18 (2000) 565-570
4. Rahman A., and Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 358 (2008) 929-939
5. Kariuki S.N., Crow M.K., and Niewold T.B. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 58 (2008) 2818-2823
6. Studnicka-Benke A., Steiner G., Petera P., and Smolen J.S. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35 (1996) 1067-1074
7. Kariuki S.N., Moore J.G., Kirou K.A., Crow M.K., Utset T.O., and Niewold T.B. Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun 10 (2009) 487-494
8. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., and Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301 (1979) 5-8
9. Niewold T.B. Interferon alpha-induced lupus: proof of principle. J Clin Rheumatol 14 (2008) 131-132
10. Crow M.K. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 316 (2007) 359-386
11. Baechler E.C., Batliwalla F.M., Karypis G., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100 (2003) 2610-2615
12. Fairhurst A.M., Wandstrat A.E., and Wakeland E.K. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol 92 (2006) 1-69
13. Crow M.K., Kirou K.A., and Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36 (2003) 481-490
14. Hua J., Kirou K., Lee C., and Crow M.K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 54 (2006) 1906-1916
15. Niewold T.B., Hua J., Lehman T.J., Harley J.B., and Crow M.K. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8 (2007) 492-502
16. Landolt-Marticorena C., Bonventi G., Lubovich A., et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in Systemic Lupus Erythematosus. Ann Rheum Dis 68 (2009) 1440-1446
17. Moser K.L., Kelly J.A., Lessard C.J., and Harley J.B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 10 (2009) 373-379
18. Harley I.T., Kaufman K.M., Langefeld C.D., Harley J.B., and Kelly J.A. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 10 (2009) 285-290
19. Takaoka A., and Yanai H. Interferon signalling network in innate defence. Cell Microbiol 8 (2006) 907-922
20. Kirou K.A., Lee C., George S., Louca K., Peterson M.G., and Crow M.K. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52 (2005) 1491-1503
21. Ytterberg S.R., and Schnitzer T.J. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 25 (1982) 401-406
22. Niewold T.B., Kelly J.A., Flesch M.H., Espinoza L.R., Harley J.B., and Crow M.K. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 58 (2008) 2481-2487
23. Ronnblom L.E., Alm G.V., and Oberg K.E. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 227 (1990) 207-210
24. Niewold T.B., and Swedler W.I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 24 (2005) 178-181
25. Tsao B.P., Grossman J.M., Riemekasten G., et al. Familiality and co-occurrence of clinical features of systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2678-2685
26. Ramos P.S., Kelly J.A., Gray-McGuire C., et al. Familial aggregation and linkage analysis of autoantibody traits in pedigrees multiplex for systemic lupus erythematosus. Genes Immun 7 (2006) 417-432
27. Ioannou Y., and Isenberg D.A. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43 (2000) 1431-1442
28. Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 16 (2002) 847-858
29. Lopez P., Mozo L., Gutierrez C., and Suarez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus 12 (2003) 860-865
30. Szyper-Kravitz M., Zandman-Goddard G., Lahita R.G., and Shoenfeld Y. The neuroendocrine-immune interactions in systemic lupus erythematosus: a basis for understanding disease pathogenesis and complexity. Rheum Dis Clin North Am 31 (2005) 161-175
31. van Vollenhoven R.F., Engleman E.G., and McGuire J.L. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 37 (1994) 1305-1310
32. Chagnon P., Schneider R., Hebert J., et al. Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus. Arthritis Rheum 54 (2006) 1270-1278
33. Stevens A.M., Tsao B.P., Hahn B.H., et al. Maternal HLA class II compatibility in men with systemic lupus erythematosus. Arthritis Rheum 52 (2005) 2768-2773
34. Niewold T.B., Adler J.E., Glenn S.B., Lehman T.J., Harley J.B., and Crow M.K. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum 58 (2008) 2113-2119
35. Denhardt D.T., and Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 30-31 (1998) 92-102
36. Lampe M.A., Patarca R., Iregui M.V., and Cantor H. Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease. J Immunol 147 (1991) 2902-2906
37. Scatena M., Liaw L., and Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27 (2007) 2302-2309
38. Masutani K., Akahoshi M., Tsuruya K., et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 44 (2001) 2097-2106
39. Chabas D., Baranzini S.E., Mitchell D., et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294 (2001) 1731-1735
40. Shinohara M.L., Lu L., Bu J., et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 7 (2006) 498-506
41. Forton A.C., Petri M.A., Goldman D., and Sullivan K.E. An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus. Hum Mutat 19 (2002) 459
42. D'Alfonso S., Barizzone N., Giordano M., et al. Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 52 (2005) 539-547
43. Han S., Guthridge J.M., Harley I.T., et al. Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS ONE 3 (2008) e0001757
44. Vanacker J.M., Delmarre C., Guo X., and Laudet V. Activation of the osteopontin promoter by the orphan nuclear receptor estrogen receptor related alpha. Cell Growth Differ 9 (1998) 1007-1014
45. Lee Y.H., Rho Y.H., Choi S.J., et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases-a meta-analysis. Rheumatology 46 (2007) 49-56
46. Mavragani C.P., Danielides S., Niewold T.B., Kirou K.A., Moutsopoulos H.M., and Crow M.K. Activation of the type I interferon pathway in autoimmune thyroid disease. Arthritis Rheum 56 (2007) S229
47. Palucka A.K., Blanck J.P., Bennett L., Pascual V., and Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 102 (2005) 3372-3377
48. Devendra D., and Eisenbarth G.S. Interferon alpha-a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 111 (2004) 225-233
49. Walker J.G., Ahern M.J., Coleman M., et al. Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 992-999
50. Roelofs M.F., Wenink M.H., Brentano F., et al. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Ann Rheum Dis 68 (2009) 1486-1493
51. Barrett J.C., Hansoul S., Nicolae D.L., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40 (2008) 955-962
52. Rutgeerts P., Vermeire S., and Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 136 (2009) 1182-1197
53. Vang T., Miletic A.V., Bottini N., and Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 40 (2007) 453-461
54. Rieck M., Arechiga A., Onengut-Gumuscu S., Greenbaum C., Concannon P., and Buckner J.H. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 179 (2007) 4704-4710
55. Pierer M., Kaltenhauser S., Arnold S., et al. Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients. Arthritis Res Ther 8 (2006) R75
56. Dastmalchi M., Grundtman C., Alexanderson H., et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67 (2008) 1670-1677
57. Mavragani C.P., Niewold T.B., Moutsopoulos N.M., Pillemer S.R., Wahl S.M., and Crow M.K. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 56 (2007) 3995-4004
58. Tyler D.R., Persky M.E., Matthews L.A., Chan S., and Farrar J.D. Pre-assembly of STAT4 with the human IFN-alpha/beta receptor-2 subunit is mediated by the STAT4 N-domain. Mol Immunol 44 (2007) 1864-1872
59. Remmers E.F., Plenge R.M., Lee A.T., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357 (2007) 977-986
60. Sigurdsson S., Nordmark G., Garnier S., et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 17 (2008) 2868-2876
61. Korman B.D., Alba M.I., Le J.M., et al. Variant form of STAT4 is associated with primary Sjogren's syndrome. Genes Immun 9 (2008) 267-270
62. Prahalad S., Hansen S., Whiting A., et al. Variants in TNFAIP3, STAT4, and C12orf30 loci associated with multiple autoimmune diseases are also associated with juvenile idiopathic arthritis. Arthritis Rheum 60 (2009) 2124-2130
63. Bave U., Nordmark G., Lovgren T., et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 52 (2005) 1185-1195
64. Niewold T.B., Rivera T.L., Buyon J.P., and Crow M.K. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum 58 (2008) 541-546
65. Taylor K.E., Remmers E.F., Lee A.T., et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 4 (2008) e1000084
66. Kariuki S.N., Kirou K.A., MacDermott E.J., Barillas-Arias L., Crow M.K., and Niewold T.B. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 182 (2009) 34-38
67. Jacob C.O., and McDevitt H.O. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 331 (1988) 356-358
68. Aringer M., and Smolen J.S. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 10 (2008) 202
69. Yao Y., Richman L., Higgs B.W., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 60 (2009) 1785-1796
70. Fan K., Dai J., Wang H., et al. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum 58 (2008) 2041-2052